Pharmaceutical Membrane Filtration Market - Size, Share, Industry Trends, and Forecasts (2025 - 2035)

Growing Biosimilar and Biologic Drug Development Boost Demand

The pharmaceutical membrane filtration market is expanding due to the growth of biologic and biosimilar drug development. Biologic drugs are complex molecules obtained from living organisms. The manufacturing of biologic drugs involves the use of advanced purification techniques and sterile membrane filtration technologies. Membrane filtration is commonly used during the production of biologic drugs to remove host cell contaminants, virus contaminants, and impurities.

For instance, according to the U.S. Biosimilar Market Entry Challenges and Facilitating Factors Final Report (2025)" published by the United States Department of Health and Human Services, "The FDA had approved 63 biosimilars of 18 reference biologic products by the end of 2024.

Therefore, the growth of biosimilar and biologic drug production is creating a need for pharmaceutical membrane filtration technologies.

Increasing Prevalence of Chronic Diseases

The incidence of chronic diseases, including cancer, diabetes, and cardiovascular diseases, is rising, which in turn increases the need to produce drugs on a large scale. Pharmaceutical companies are increasing the production of drugs to cater to the treatment requirements of these diseases, which in turn increases the need for membrane filtration technologies. The need to produce drugs on a large scale increases the use of microfiltration and ultrafiltration technologies in the upstream and downstream processes. For example, World Health Organization, chronic diseases are likely to cause 90 million deaths annually by the year 2048, which translates to 86% of the total deaths if the current trend continues.

CMO Expansion Increases Filtration Outsourcing

The expansion of CMOs results in the outsourcing of drug manufacturing activities for pharmaceutical and biopharmaceutical companies. Outsourcing of production activities demands flexible and scalable filtration systems to accommodate different product pipelines. CMOs invest heavily in advanced membrane filtration technologies to ensure high throughput and meet strict regulations for different client projects. For instance, CPHI estimates that by 2028, 40% of global capacity for biologics production is expected to be handled by CMOs, while 45% of this capacity is expected to be located in Asia. This trend is expected to promote the use of single-use and modular filtration systems for increased operational efficiency and reduced turn-around time.

High Filtration System Cost and Membrane Fouling Issues Are Restraining the Market Growth

Pharmaceutical membrane filtration systems need specialized membranes, filtration units, and monitoring equipment. Pharmaceutical membrane filtration systems are costly in terms of initial investment and maintenance. Smaller pharmaceutical manufacturers may face difficulty adopting advanced filtration technologies. Thus, the high system costs involved and the fouling of the membranes are factors that restrain the growth of the pharmaceutical membrane filtration market.

Adoption Of Membrane-Based Systems for Water-For-Injection Production Creates Future Opportunities

The pharmaceutical industry is increasingly employing advanced membrane filtration technologies to enhance efficiency in the processes involved. Water for Injection (WFI) is an essential component that is utilized for the manufacture of injectable pharmaceutical products. The conventional method of producing WFI is distillation. For instance, in June 2024, Asahi Kasei has commenced the sale of a membrane system for the manufacture of Water for Injection (WFI) utilizing the Microza hollow fiber membranes. This is an alternative to the distillation method while ensuring the efficiency of the system is maximized. Thus, it is, therefore, expected that the application of membrane-based WFI production systems will boost the efficiency of the pharmaceutical manufacturing process.

Biosimilars & Advanced Therapies Boost Filtration Need Creates Opportunity

The increased investment in biosimilars and advanced therapy technologies, cell therapy, and gene therapy requires high precision in filtration technologies. The need for precise control over contaminants and the nature of the biological molecule is significant in the production of cell therapy and gene therapy. The membrane filtration system plays an important role in the critical separation and purification steps in the production of biologics. The increased pipeline of complex biologics requires specialized filtration technologies with high selectivity and performance, hence contributing to the growth of the market. In January 2026, Toray Industries, Inc., developed a new membrane filtration technology with improved separation efficiency and lower energy consumption.